Grifols begins clinical trial of anti-SARS-CoV-2 hyperimmune globulin in patients with COVID-19
Grifols, a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people’s health and well-being, announced that its anti-SARS-CoV-2 hyperimmune globulin,...
Recent Comments